0
     

Report Added
Report already added
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III.

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and Alzheimer's Disease.

The latest report N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2022, outlays comprehensive information on the N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)
- The report reviews N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Amicus Therapeutics Inc
ArmaGen Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
JCR Pharmaceuticals Co Ltd
Lysogene SAS
Tega Therapeutics Inc
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles
AGT-184 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-126 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EGT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate SGSH for Mucopolysaccharidosis Type IIIA - Drug Profile
Product Description
Mechanism Of Action
History of Events
JR-441 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LYSSAF-302 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rebisufligene etisparvovec - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Enzyme to Replace Sulphamidase for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Drug Profile
Product Description
Mechanism Of Action
History of Events
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Dormant Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones
Featured News & Press Releases
Feb 24, 2022: Lysogene provides update on efficacy, safety and timelines of the AAVance Phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA
Feb 11, 2022: Lysogene reports additional positive biomarker data with LYS-SAF302 presented at the WORLDSymposium 2022
Feb 03, 2022: JCR pharmaceuticals to present posters on JR-441 at the 18th annual WORLDSymposium 2022
Jan 21, 2022: EC grants orphan drug designation to JR-441 for the treatment of mucopolysaccharidosis type III A (MPS IIIA)
Nov 17, 2021: Abeona Therapeutics announces presentation on pivotal Transpher A study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
Oct 13, 2021: Abeona Therapeutics announces clinical data presentations at upcoming scientific congresses
Jul 28, 2021: Abeona Therapeutics announces successful Type B meeting with U.S. FDA for ABO-102 AAV-based gene therapy in Sanfilippo Syndrome Type A (MPS IIIA)
Jul 26, 2021: Abeona Therapeutics announces new MRI data showing increased brain volume in young patients with Sanfilippo Syndrome Type A (MPS IIIA) after treatment with ABO-102 gene therapy
Feb 15, 2021: Lysogene reports LYS-SAF302 biomarker data presented at the WORLDSymposium 2021
Feb 12, 2021: New positive interim data on ABO-102 presented at WORLDSymposium
Feb 02, 2021: Abeona Therapeutics announces clinical investigator webinar to review ABO-102 Clinical Data presented at the 17th Annual WORLDSymposium
Dec 28, 2020: Lysogene reports positive biomarker data with LYS-SAF302
Dec 21, 2020: Abeona Therapeutics announces acceptance of late-breaker abstracts highlighting new clinical data for novel AAV-based gene therapies including rebisufligene etisparvovec at WORLDSymposium
Oct 15, 2020: Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA
Jun 05, 2020: Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Abeona Therapeutics Inc, 2022
Pipeline by Amicus Therapeutics Inc, 2022
Pipeline by ArmaGen Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Esteve Pharmaceuticals SA, 2022
Pipeline by JCR Pharmaceuticals Co Ltd, 2022
Pipeline by Lysogene SAS, 2022
Pipeline by Tega Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline